Therapeutic drug monitoring in pediatric inflammatory bowel disease

Namita Singh, Marla C. Dubinsky

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

Abstract

Therapeutic drug monitoring (TDM) is the clinical practice of measuring drug concentrations to attain a targeted serum concentration and thus optimizing individual dosage regimens. TDM has emerged as a necessary mechanism to enhance drug efficacy to achieve optimal outcomes. Examples include the well-established relationship of the genetic variability of thiopurine metabolism driven by the thiopurine S-methyltransferase (TPMT) pathway, and data supporting the pharmacokinetic variability and immunogenicity with anti-tumor necrosis factor (TNF) therapies. In this chapter, we review the data describing the relationship between drug concentrations and outcomes. The effect of anti-drug antibodies on drug efficacy and toxicity has been established. Furthermore, we describe different assays which are used in measuring these drug and antibody concentrations. An algorithm is proposed for clinical practitioners to utilize TDM in the patients losing clinical response to anti-TNF therapy. The limited data around drug and antibody concentrations for vedolizumab and ustekinumab and relation to outcomes are introduced. A proactive, rather than reactive, approach to TDM of anti-TNF agents is supported by emerging data and will provide practitioners with the tools needed to optimally treat young IBD patients.

Original languageEnglish
Title of host publicationPediatric Inflammatory Bowel Disease
PublisherSpringer International Publishing
Pages445-456
Number of pages12
ISBN (Electronic)9783031147449
ISBN (Print)9783031147432
DOIs
StatePublished - 27 Feb 2023

Keywords

  • Anti-TNF trough concentration
  • Anti-drug antibodies
  • Immunomodulator
  • Inflammatory bowel disease
  • Infliximab trough concentration
  • Pharmacokinetics
  • Therapeutic drug monitoring
  • Thiopurine metabolites
  • Ustekinumab
  • Vedolizumab

Fingerprint

Dive into the research topics of 'Therapeutic drug monitoring in pediatric inflammatory bowel disease'. Together they form a unique fingerprint.

Cite this